.png){kind=logo}
™
Unlocking first-in-class biologics with genetics-inspired functional screening at scale.
Pipeline
Where molecules meet innovation
Assets for Commercial Development
Number of Lead Molecules
2 recombinant human Interferon-beta variants
Therapeutic area
Autoimmune Disease
Disease
Clinical Need
Reduced immunogenicity
Current SOC/Market:
Rebif®* (Interferon beta-1a); Merck KGaA
Immunosuppressant
~$4B IFN-β market
Supporting Data:
Precision glycosylated biobetters
Lower EC50
Designed for reduced immunogenicity
Status:
_________________________________________________________________________
Number of Lead Molecules
>500 recombinant human Interferon-beta variants
Therapeutic area
Autoimmune Disease
Disease
Clinical Need
Reduced immunogenicity
Current SOC/Market:
Rebif®* (Interferon beta-1a); Merck KGaA
Immunosuppressant
~$4B IFN-β market
Supporting Data:
Comparable EC50 to reference drug
Status:
_________________________________________________________________________
Number of Lead Molecules
1 Interferon hybrid
Therapeutic area
Autoimmune Disease
Disease
Multiple Sclerosis
Clinical Need
Reduced immunogenicity
Current SOC/Market:
Rebif®* (Interferon beta-1a); Merck KGaA
Immunosuppressant
~$4B IFN-β market
Supporting Data:
Hybrid molecule of two genes
Increased potency
Status:
_________________________________________________________________________
Number of Lead Molecules
>350 recombinant human Interferon-α2 variants
Therapeutic area
Cancer, Immunology
Disease
Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera, Hepatitis D
Clinical Need
Susceptible to relapse
Current SOC/Market
Pegasys®* (peginterferon alfa-2); Genentech
Blocks relapse
~$2B AML market
Supporting Data
Precision post-translational modifications
Precision guided disulfide bonds
Various modifications for improved potency
Status:
_________________________________________________________________________
Number of Lead Molecules
>1600 recombinant human Interferon-α2 variants
Therapeutic area
Cancer, Immunology
Disease
Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera, Viral Infection
Clinical Need
Susceptible to relapse
Current SOC/Market
Pegasys®* (peginterferon alfa-2); Genentech
Blocks relapse
~$2B AML market
Supporting Data
Precision post-translational modifications
Precision guided disulfide bonds
Various modifications for improved potency
Status:
_________________________________________________________________________
Number of Lead Molecules
16 recombinant human interferon chimeras
Therapeutic area
Cancer, Immunology
Disease
Acute Myeloid Leukemia, Squamous Cell Carcinoma, Polycythemia Vera, Viral Infection
Clinical Need
Limited efficacy
Current SOC/Market
Pegasys®* (peginterferon alfa-2); Genentech
Immune modulator
~$3B IFN-alpha2 market
Supporting Data
Dual gene agonist
Improved activity compared to IFN-alpha2
Status:
_________________________________________________________________________
*Manufactured drugs are registered trademarks of third parties.
Number of Lead Molecules
TBD; variant libraries are currently being designed to thousands of unique GLP-1 variants with our powerful cell-based GigaAssay platform—engineered to discover leads with superior potency, enhanced stability, and lower immunogenicity compared to current reference products.
Therapeutic area
Metabolic disorder
Disease
Clinical Need
Limited potency
Immunogenic
GI-related side effects
Current SOC/Market:
Semaglutide® * (GLP-1) (Novo Nordisk)
Improved glycemic control, weight management
~$60B GLP-1 market
Supporting Data:
TBD
Status:
_________________________________________________________________________
Number of Lead Molecules
TBD; variant libraries are currently being designed to thousands of unique GLP-1 variants with our powerful cell-based GigaAssay platform—engineered to discover leads with similar potency, enhanced stability, and lower immunogenicity compared to current reference products.
Therapeutic area
Metabolic disorder
Disease
Clinical Need
Limited potency
Immunogenic
GI-related side effects
Current SOC/Market:
Semaglutide® * (GLP-1) (Novo Nordisk)
Improved glycemic control, weight management
~$60B GLP-1 market
Supporting Data:
TBD
Status:
_________________________________________________________________________
Number of Lead Molecules
TBD; variant libraries are currently being designed to unlock thousands of proprietary Incretin (GLP-1, GIP, GCG) variants, rapidly designed and tested in our high-throughput cell-based GigaAssay. We will discover optimized, balanced leads with superior potency across GLP1R, GIPR, and GCGR—delivering enhanced stability and reduced immunogenicity beyond current reference products.
Therapeutic area
Metabolic disorder
Disease
Clinical Need
Limited potency
Immunogenic
GI-related side effects
Current SOC/Market:
Retatrutide® * (Incretin tri-agonist) (Eli Lilly & Company)
Improved glycemic control, weight management
~$60B GLP-1 market
Supporting Data:
TBD
Status:
_________________________________________________________________________
*Manufactured drugs are registered trademarks of third parties.
Number of Drug Resistant Variants
>100
Therapeutic area
Cancer
Disease
HER2+ breast cancer
Clinical Need
Therapies rotated without biomarker-driven guidance
Current SOC/Market
HER2+ companion diagnostic
Key points about the significance of HER2
HER2 (human epidermal growth factor receptor 2) is a protein and gene that plays a critical role in cell growth and division. Its significance is most prominent in breast cancer, where about 20-30% of tumors display HER2 gene amplification or protein overexpression, leading to a subtype known as HER2-positive breast cancer.
Driver of Aggressive Cancer: When the HER2 gene is amplified, it causes excessive production of the HER2 protein, which in turn triggers uncontrolled cell growth. This results in a particularly aggressive subtype of breast cancer with a tendency for rapid growth and higher risk of recurrence.
Therapeutic Target: The identification of HER2 as a driver of cancer led to the development of targeted therapies, such as trastuzumab (Herceptin), which have dramatically improved the prognosis for patients with HER2-positive tumors. Effective treatment is closely linked to precise determination of HER2 status.
Clinical Decision-Making: HER2 status is now routinely tested in breast cancer diagnoses. It guides treatment decisions: tumors positive for HER2 typically benefit from anti-HER2 therapies, while those that are HER2-negative do not.
Prognosis and Predictive Value: HER2 positivity is associated with greater tumor aggressiveness and used to predict how a patient will respond to specific treatments, including certain chemotherapies and hormonal therapies.
Molecular Function: HER2 is one of four related receptors (HER1-4) on the cell surface that, when activated (usually by dimerization), trigger intracellular signaling cascades involved in proliferation and survival. Unlike other family members, HER2 does not require a ligand and acts mainly through partnering with other HER family proteins.
Supporting Data
Expanded HER2 resistance map: 6,000 variants tested -> 250+ resistance mutations identified (vs. 3 known) across 3 key drugs.
Status:
__________________________________________________________________